Contact a certified poison control center for the most up to date information on the management of SporanoxThe solution should be vigorously swished in the mouth (10 mL at a time) for several seconds and swallowed.For patients with oropharyngeal candidiasis unresponsive/refractory to treatment with fluconazole tablets, the recommended dose is 100 mg (10 mL) b.i.d. Only 0.2% of the itraconazole in plasma is present as free drug. Select one or more newsletters to continue. Contrary to plasma, the concentration in skin persists for 2 to 4 weeks after discontinuation of a 4-week treatment and in nail keratin – where itraconazole can be detected as early as 1 week after start of treatment – for at least six months after the end of a 3-month treatment period.Limited data are available on the use of oral itraconazole in patients with renal impairment.
Sporanox is used to treat infections in adults caused by fungus, which can invade any part of the body including the lungs, mouth or throat, toenails, or fingernails. Studies conducted under fasted conditions demonstrated that administration with 8 ounces of a non-diet cola beverage resulted in increased absorption of itraconazole in AIDS patients with relative or absolute achlorhydria. In another trial, the clinical response rate (defined as cured or improved) for itraconazole oral solution was similar to clotrimazole troches and averaged approximately 71% across both arms, with approximately 3% of subjects lost to follow-up before any evaluations could be performed.
It is used to treat certain kinds of fungal or yeast infections. Other substances that either share this metabolic pathway or modify CYP3A4 activity may influence the pharmacokinetics of itraconazole. The median dose was 200 mg/day.
Results of these studies demonstrated substantial evidence of effectiveness of itraconazole as a second-line therapy for the treatment of aspergillosis compared with the natural history of the disease in patients who either failed or were intolerant of amphotericin B therapy.Analyses were conducted on data from three double-blind, placebo-controlled studies (N=214 total; 110 given SPORANOXAnalyses were conducted on data from a double-blind, placebo-controlled study (N=73 total; 37 given SPORANOXCoadministration of a number of CYP3A4 substrates are contraindicated with SPORANOXLife-threatening cardiac dysrhythmias and/or sudden death have occurred in patients using drugs such as cisapride, pimozide, methadone, or quinidine concomitantly with SPORANOXFor patients with risk factors for congestive heart failure, physicians should carefully review the risks and benefits of SPORANOXItraconazole has been shown to have a negative inotropic effect. Sixteen patients completed the study. Caution should be exercised when this drug is administered in this patient population. In a healthy volunteer study of itraconazole intravenous infusion, transient, asymptomatic decreases in left ventricular ejection fraction were observed using gated SPECT imaging; these resolved before the next infusion, 12 hours later. Itraconazole exposure is greater with the oral solution than with the capsule formulation when the same dose of drug is given. In a healthy volunteer study of itraconazole intravenous infusion, transient, asymptomatic decreases in left ventricular ejection fraction were observed using gated SPECT imaging; these resolved before the next infusion, 12 hours later. Clinical response in this study was defined as cured or improved (only minimal signs and symptoms with no visible lesions). More severe signs of parental toxicity, including death, were present in the next higher dosage level, 160 mg/kg/day (20 times the MRHD).Itraconazole was found to cause a dose-related increase in maternal toxicity, embryotoxicity, and teratogenicity in rats at dosage levels of approximately 40–160 mg/kg/day (5–20 times the MRHD), and in mice at dosage levels of approximately 80 mg/kg/day (10 times the MRHD).